Logo image of GPCR

STRUCTURE THERAPEUTICS INC (GPCR) Stock Fundamental Analysis

NASDAQ:GPCR - US86366E1064 - ADR

19.3 USD
+0.16 (+0.84%)
Last: 8/29/2025, 8:27:22 PM
19.5 USD
+0.2 (+1.04%)
Pre-Market: 9/2/2025, 4:05:57 AM
Fundamental Rating

3

GPCR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 195 industry peers in the Pharmaceuticals industry. While GPCR has a great health rating, there are worries on its profitability. GPCR does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

GPCR had negative earnings in the past year.
In the past year GPCR has reported a negative cash flow from operations.
In the past 5 years GPCR always reported negative net income.
GPCR had a negative operating cash flow in each of the past 5 years.
GPCR Yearly Net Income VS EBIT VS OCF VS FCFGPCR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

GPCR has a Return On Assets (-21.92%) which is comparable to the rest of the industry.
The Return On Equity of GPCR (-23.18%) is better than 65.13% of its industry peers.
Industry RankSector Rank
ROA -21.92%
ROE -23.18%
ROIC N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
GPCR Yearly ROA, ROE, ROICGPCR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GPCR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GPCR Yearly Profit, Operating, Gross MarginsGPCR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, GPCR has more shares outstanding
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GPCR Yearly Shares OutstandingGPCR Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GPCR Yearly Total Debt VS Total AssetsGPCR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

GPCR has an Altman-Z score of 14.51. This indicates that GPCR is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 14.51, GPCR belongs to the best of the industry, outperforming 90.77% of the companies in the same industry.
GPCR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 14.51
ROIC/WACCN/A
WACCN/A
GPCR Yearly LT Debt VS Equity VS FCFGPCR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 20.48 indicates that GPCR has no problem at all paying its short term obligations.
With an excellent Current ratio value of 20.48, GPCR belongs to the best of the industry, outperforming 91.28% of the companies in the same industry.
A Quick Ratio of 20.48 indicates that GPCR has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 20.48, GPCR belongs to the top of the industry, outperforming 91.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 20.48
Quick Ratio 20.48
GPCR Yearly Current Assets VS Current LiabilitesGPCR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

1

3. Growth

3.1 Past

GPCR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -92.73%.
EPS 1Y (TTM)-92.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, GPCR will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.59% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.2%
EPS Next 2Y-0.94%
EPS Next 3Y-3.58%
EPS Next 5Y13.59%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GPCR Yearly Revenue VS EstimatesGPCR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 500M 1B 1.5B
GPCR Yearly EPS VS EstimatesGPCR Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GPCR. In the last year negative earnings were reported.
Also next year GPCR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GPCR Price Earnings VS Forward Price EarningsGPCR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GPCR Per share dataGPCR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

GPCR's earnings are expected to decrease with -3.58% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.94%
EPS Next 3Y-3.58%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for GPCR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

STRUCTURE THERAPEUTICS INC

NASDAQ:GPCR (8/29/2025, 8:27:22 PM)

Premarket: 19.5 +0.2 (+1.04%)

19.3

+0.16 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)11-11 2025-11-11/bmo
Inst Owners99.97%
Inst Owner Change-0.65%
Ins Owners3.08%
Ins Owner Change29.35%
Market Cap1.11B
Analysts86.32
Price Target77.68 (302.49%)
Short Float %39.44%
Short Ratio8.57
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-265.43%
Min EPS beat(2)-283.91%
Max EPS beat(2)-246.94%
EPS beat(4)0
Avg EPS beat(4)-237.39%
Min EPS beat(4)-283.91%
Max EPS beat(4)-202.27%
EPS beat(8)2
Avg EPS beat(8)-154.45%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.98%
PT rev (3m)-3.25%
EPS NQ rev (1m)-24.04%
EPS NQ rev (3m)-31.13%
EPS NY rev (1m)-31.08%
EPS NY rev (3m)-5.11%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.44
P/tB 1.44
EV/EBITDA N/A
EPS(TTM)-3.18
EYN/A
EPS(NY)-1.69
Fwd EYN/A
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-2.83
OCFYN/A
SpS0
BVpS13.4
TBVpS13.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.92%
ROE -23.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.72%
ROA(5y)-33.39%
ROE(3y)-32.08%
ROE(5y)-36.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 113.06%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.48
Quick Ratio 20.48
Altman-Z 14.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)306.86%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-92.73%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next Y15.2%
EPS Next 2Y-0.94%
EPS Next 3Y-3.58%
EPS Next 5Y13.59%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-79.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.84%
EBIT Next 3Y-30.31%
EBIT Next 5Y-5.94%
FCF growth 1Y-44.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.73%
OCF growth 3YN/A
OCF growth 5YN/A